Response to the comments of Reviewer 3

General comment: "*In the impressive review, the authors firstly give an overall introduction on EVs and their relationship with disease. Followingly, they provide a detailed pathophysiology and classification of TNBC and the in-depth understanding of the crucial roles of the EVs in the growth and metastatic dissemination of TNBC, its immune regulation, and their contribution as a predictive biomarker for TNBC. Finally, they focus on the recent key advances in immunotherapeutic strategies for better understanding the complex interplay between EVs and the immune system in TNBC and further developing EV-based targeted immunotherapies. Overall, this review is well organized on the summarization of EVs in immune regulation, biomarker, and immunotherapeutic potential for TNBC and should be published on Cancers except for some minor revisions.*"

Response: First of all, we would like to thank the reviewer for finding our review impressive, well-organized and of potential interest in the field of TNBC. However, the reviewer has raised a minor concern which we tried our best to address.

Comment 1: "*In the section of EVs in TNBC immunotherapy, the authors mainly focus on the immune cell derived EVs and self-loaded bioactive molecules as immunotherapeutic against TNBC. Other cells derived EVs (especially TNBC tumor cell themselves) as the delivery platform or camouflage coating and loaded cargos such as immunomodulator and nanoparticles should also be fully summarized.*"

Response: Taking the reviewer's valuable suggestions, we have included a paragraph in our revised manuscript (page 18-19, line 619-635) where we address the concern raised by the reviewer.